Pay in 4 interest-free payments of $6.62 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
Side effects by dose level Nausea management protocol These strategies come from clinical practice and community experience
Off-label use is less common compared to HGH but is still prevalent in anti-aging and wellness clinics and its affordability makes it more appealing to many patients
It transformed obesity treatment as the first weekly GLP-1 for chronic weight management and currently supports nearly 1.5 million patients in the U.S
Data sources and search strategy Systematic searches were conducted in PubMed, Medline, Embase, the Cochrane Center Register of Controlled Trials for Studies, and Clinicaltrials.gov last updated on March 8, 2024
Last reviewed: April 21, 2026 Updated with Phase 3 TRIUMPH-4 data Primary sources: NEJM, Eli Lilly, ClinicalTrials.gov Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) currently in Phase 3 trials, showing stronger early weight loss data
US$ 22.00
US$ 24.68
US$ 23.72
US$ 29.70
US$ 29.54
US$ 26.21
US$ 23.33
US$ 23.98
